British drug major AstraZeneca (AZN.L, AZN) and MedImmune Inc. (MEDI), the company's global biologics research and development arm, said Tuesday that they presented data on overall survival or OS in the Phase III PACIFIC trial of Imfinzi, during the Presidential Symposium of the IASLC 19th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Toronto, Canada.